Icotrokinra is an investigational oral peptide that blocks interleukin (IL)-23 receptor, which plays a significant role in ...

Results for icotrokinra (JNJ-2113) have shown the drug’s potential to offer significant relief for patients suffering from moderate-to-severe plaque psorias ...

Topline results were announced from a phase 3 trial evaluating icotrokinra in patients with moderate to severe plaque psoriasis (PsO).

Johnson & Johnson has reported positive outcomes from its Phase III trial of oral icotrokinra for treating plaque psoriasis.

The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the chronic skin condition.

It is also less expensive than some of the newer psoriasis treatments. Vtama (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist that was approved in 2022 for the treatment of mild, moderate ...

While PASI lists redness as a measure, your psoriasis may be different, depending on your natural skin color. Plaques may appear purple, brown, or ashen gray on dark-skinned individuals. Generally ...

The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down ...

One woman’s journey from receiving her diagnosis to finding a treatment that helps manage her chronic skin condition.

Johnson & Johnson (J&J) and Protagonist Therapeutics have announced positive top-line results from a late-stage study of ...